Navigation Links
New technique helps researchers determine amino-acid charge

Measurements of the ion-current through the open state of a membrane-protein's ion channel have allowed scientists at the University of Illinois at Urbana-Champaign to obtain a detailed picture of the effect of the protein microenvironment on the affinity of ionizable amino-acid residues for protons.

The findings, reported in the Dec. 15 issue of Nature, are expected to be welcome news for chemists and biophysicists, both experimentalists and theoreticians, because they have previously relied on theoretical estimations to predict protonation states -- whether an amino acid is charged or not. Appropriate experimental benchmarks also had been lacking.

All cells have membrane proteins that form channels to allow water and/or ions to pass through. Malfunctions have been linked to such problems as hypertension, abnormal insulin secretion, abnormal heart conditions and brain seizures. As a result, these membrane proteins are often targeted by drug treatments.

Previous approaches didn't provide sufficient resolution to let researchers accurately detect the association and dissociation of protons to and from individual amino-acid residues in real time.

Using the patch-clamp technique, the researchers were able to probe the electrostatic properties of the inner lining of the ion-channel's pore, and, from there, they inferred the rotational angle of the pore-lining alpha-helices in the open state.

In this case, researchers focused on the muscle nicotinic acetylcholine receptor, a membrane protein that mediates voluntary muscle contraction.

"Our paper has implications that are specific to this receptor, but many of the findings can be extended to several other membrane proteins," said Claudio Grosman, a professor of molecular and integrative physiology at Illinois.

"We are working with the open state of the ion channel, and we now know how the helices that line the pore are oriented. This was not known before," Grosman sai
'"/>

Source:University of Illinois at Urbana-Champaign


Page: 1 2

Related biology news :

1. New lab technique identifies high levels of pathogens in therapy pool
2. Brain-mapping technique aids understanding of sleep, wakefulness
3. Study reveals new technique for fingerprinting environmental samples
4. Researchers pioneer new gene therapy technique using natural repair process
5. Newer imaging techniques may lead to over-treatment
6. Gene silencing technique offers new strategy for treating, curing disease
7. Mosaic mouse technique offers a powerful new tool to study diseases and genetics
8. Researchers devise new technique for creating human stem cells
9. New technique rapidly detects illness-causing bacteria
10. New bioinformatics technique for systematically analyzing key regions in DNA that help control gene activity
11. New technique may speed DNA analysis
Post Your Comments:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5